Abstract:BACKGROUND AND OBJECTIVE:Cisplatin-resistance in lung cancer cells is general in clinic, hence it is significant to investigate the mechanisms of cisplatin-resistant and develop new methods of reversing drug-resistance. Recent researches showed that miRNA could regulate cell growth, apoptosis, migration and invasion even in drug therapy in cancer by its target gene. The aim of this study is to investigate the effects and molecular mechanisms of miR-503 on reversing the cisplatin-resistance in lung cancer DDP-resistant cell line A549/DDP.METHODS:MTS assay was employed to determine the effect of miR-503 on A549/DDP' sensitivity to cisplatin. Apoptosis rate and intracellular concentration of rhodamine-123 (Rh-123) were determined by flow cytometry, the expression of multi-drugs resistant proteins MDR1 and MRP1, ERCC1, RhoE, Survivin and Bcl-2 were determined by Western blot and real time PCR. The phosphorylation of Akt was analyzed by Western blot, the transcriptional activities of NF-κB and AP-1 were detected by dual-luciferase reporter gene systems.RESULTS:MiR-503 was able to increase the cisplatin sensitivity of A549/DDP. After treatment with miR-503, the reverse folds (RF) to cisplatin was 2.48 fold, the intracellular level of Rh-123 was 2.49 fold, the apoptosis rate was 10.3 fold, the expressions of several drug-resistant related proteins, such as MDR1, MRP1, ERCC1, Survivin and Bcl-2 were downregulated significantly, as shown by WB, in contrast, the level of RhoE was elevated, the mRNA epression of MDR1 was 18.5%, the mRNA epression of MRP1 was 22.3%, the mRNA epression of ERCC1 was 18.6%, the mRNA epression of Survivin was 42.8%, the mRNA expression of Bcl-2 was 68.1%, the mRNA epression of RhoE was 206.5%, in addition, the phosphorylation of Akt decreased and transcriptional activities of NF-κB was 53.7%, AP-1 was 47.4% compared with control group.CONCLUSIONS:MiR-503 was able to reverse the cisplatin resistance of A549/DDP. MiR-503 processed this kind of effect by inhibiting the drug efflux, downregulating the expression of drug-resistant related proteins and promoting cell apoptosis.

Mir-340 Reverses Cisplatin Resistance Of Hepatocellular Carcinoma Cell Lines By Targeting Nrf2-Dependent Antioxidant Pathway

Mir‑144‑3p Regulates the Resistance of Lung Cancer to Cisplatin by Targeting Nrf2.

Downregulation of Mir-33A-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.

MicroRNA-191 Modulates Cisplatin-Induced DNA Damage Response by Targeting RCC2.

Upregulated Mir-182 Increases Drug Resistance in Cisplatin-Treated HCC Cell by Regulating TP53INP1.

Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies

Mir-324-3p Reverses Cisplatin Resistance by Inducing GPX4-mediated Ferroptosis in Lung Adenocarcinoma Cell Line A549

Cisplatin-induced Downregulation of Mir-199A-5p Increases Drug Resistance by Activating Autophagy in HCC Cell.

The Reversing and Molecular Mechanisms of Mir-503 on the Drug-resistance to Cisplatin in A549/DDP Cells

MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer.

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

DNA Damage Responsive Mir-33B-3p Promoted Lung Cancer Cells Survival and Cisplatin Resistance by Targeting P21waf1/cip1

Mir-133B Reverses Cisplatin Resistance by Targeting GSTP1 in Cisplatin-Resistant Lung Cancer Cells.

The role of microRNA in cisplatin resistance or sensitivity

Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP)

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

Mir-488 Inhibits Proliferation And Cisplatin Sensibility In Non-Smallcell Lung Cancer (Nsclc) Cells By Activating The Eif3a-Mediated Ner Signaling Pathway

The Role of miRNAs in Cisplatin-Resistant HeLa Cells.

Upregulated Mir-130A Increases Drug Resistance by Regulating RUNX3 and Wnt Signaling in Cisplatin-Treated HCC Cell

MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers

Mir-135A/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1